CHAPEL HILL, N.C., March 11 /PRNewswire/ -- With patent expiration a looming concern across the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It's against this backdrop that new product planning groups across biopharma are trying to deal more effectively with the twin pressures of meeting timelines and delivering commercial insights.

A recent data-rich benchmarking study from Best Practices, LLC delivers actionable insights on the critical elements of the new product planning (NPP) function. The study, "Pharmaceutical New Product Planning: Structure and Activities to Drive Growth and Profitability," identifies the full set of activities that NPP groups perform across the development cycle as well as the structure and roles of NPP groups.

To download a complimentary study excerpt, go to: http://www3.best-in-class.com/rr992.htm.

The research project illustrated that as companies move through each successive development Phase, the actual nature of assessment activities changes. For instance, many companies stated that competitive assessments and lifecycle planning made in the early stages are somewhat speculative, primarily designed to spot opportunities. Later on these activities become more specific, designed to drive forecasts.

While most companies perform competitive assessments from pre-clinical all the way through Phase 3, study participants said the activity is particularly critical in pre-clinical because:

• It can gauge what changes will occur in the years ahead
• It helps with understanding the disease state and where competitors' products fit in
• It informs how well your drug will fit in the market
• It helps frame "go, no-go" analysis so that, as data comes in, competitive assessment can drive forecasting and profitability potential
• The research examines dozens of NPP developmental activities in terms of timing during the development process, intended outcomes and value for the organization.

In addition, the study details the strengths and weaknesses of various NPP organizational structures and how the operational characteristics of the NPP function evolve as a company matures.

To review samples of key metrics and findings in the report, download a complimentary study excerpt at: http://www3.best-in-class.com/rr992.htm.

Best Practices, LLC used both field surveys and interviews to complete this study. In all, 27 New Product Planning leaders at 25 pharma companies across the globe contributed data. In-depth interviews were conducted with leaders from 13 of the participating companies. The research report reflects the current state of New Product Planning efforts at best-in-class organizations such as Abbott, Astellas, Bayer, Daiichi Sankyo, Eli Lilly, Merck, Novartis, sanofi aventis, Wyeth and others.

To learn more about Best Practices' other timely research visit: http://www3.best-in-class.com or contact Jeff Zimmer at 919-767-9180 or jzimmer@best-in-class.com.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. 

SOURCE Best Practices, LLC

Back to top

RELATED LINKS
http://www.best-in-class.com